Leap Therapeutics Inc LPTX:NASDAQ

Last Price$2.11NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.09 (5)
Ask (Size)$2.13 (50)
Day Low / HighN/A - N/A
Volume3.5 M

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Leap Therapeutics Inc ( NASDAQ )

Price: $2.11
Change: -0.28 (11.72%)
Volume: 3.5 M
4:00PM ET 1/21/2022

Athersys Inc ( NASDAQ )

Price: $0.80
Change: -0.04 (4.53%)
Volume: 1.8 M
4:00PM ET 1/21/2022

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $3.25
Change: -0.22 (6.34%)
Volume: 915.2 K
4:00PM ET 1/21/2022

9 Meters Biopharma Inc ( NASDAQ )

Price: $0.75
Change: -0.04 (5.10%)
Volume: 2.5 M
4:00PM ET 1/21/2022

Homology Medicines Inc ( NASDAQ )

Price: $3.37
Change: -0.13 (3.71%)
Volume: 368.2 K
4:00PM ET 1/21/2022

Read more news Recent News

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
9:12AM ET 1/19/2022 MT Newswires

Health care stocks were edging higher premarket Wednesday. The iShares Biotechnology ETF (IBB) was up by 0.64% while the Health Care SPDR (XLV) was 0.02%...

Leap Therapeutics to Report 'Encouraging Results' From Phase 2a Trial of Combination Treatment for Gastric Cancer -- Shares Jump in Pre-Market
6:06AM ET 1/19/2022 MT Newswires

Leap Therapeutics (LPTX) said late on Tuesday the combination of anti-Dickkopf-1, or DKN-01, with tislelizumab "continues to demonstrate encouraging...

-- Earnings Flash (LPTX) LEAP THERAPEUTICS Posts Q3 Revenue $375,000
7:01AM ET 11/12/2021 MT Newswires


--Mizuho Securities Starts Leap Therapeutics at Buy With $6 Price Target
7:27AM ET 10/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
4:17PM ET 11/29/2021 Seeking Alpha

Leap Therapeutics: Another Leap Coming Up
8:00AM ET 10/15/2021 Seeking Alpha

Leap Therapeutics: All On The Line
11:23PM ET 10/12/2021 Seeking Alpha

Leap Therapeutics (LPTX) ESMO 2021Virtual Congress Presentation - Slideshow
7:16PM ET 9/24/2021 Seeking Alpha

Company Profile

Business DescriptionLeap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. View company web site for more details
Address47 Thorndike Street
Cambridge, Massachusetts 02141
Number of Employees25
Recent SEC Filing01/18/20228-K
President, CEO, CFO, Secretary & TreasurerDoug E. Onsi
Chief Operating OfficerAugustine J. Lawlor
Chief Medical OfficerCynthia Sirard
Head-ResearchMichael Haas

Company Highlights

Price Open$2.26
Previous Close$2.39
52 Week Range$1.33 - 4.17
Market Capitalization$186.4 M
Shares Outstanding88.3 M
SectorHealth Technology
Next Earnings Announcement03/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.47
Beta vs. S&P 500N/A
Net Profit Margin-2,433.93%
Return on Equity-63.02%

Analyst Ratings as of 10/01/2021

Consensus RecommendationConsensus Icon
Powered by Factset